  The COVID19 pandemic has highlighted the lack of resilience in supply chains,
as global networks fail from disruptions at single nodes and connections.
Through an overview of the existing vaccine and pharmaceutical supply chain
publications focusing on resilience, as well as recent papers reporting
modeling of resilience in supply chains across multiple fields, we find that
models for supply chain resilience are few and most of them are focused on
individual dimensions of resilience rather than on comprehensive strategy
necessary for scaling up vaccine production and distribution in emergency
settings. We find that COVID19 resulted in a wave of interest to supply chain
resilience, but publications from 2020 are narrow in focus and largely
qualitative in nature; evidence-based models and measures are rare. Further,
publications often focus exclusively on specific portions of the specific
supply chain of interest, excluding associated supporting networks, such as
transportation, social and command and control (C2) necessary for vaccine
production and equitable distribution. This lack of network analysis is a major
gap in the literature that needs to be bridged in order to create methods of
real-time analysis and decision tools for the COVID19 vaccine supply chain. We
conclude that a comprehensive, quantitative approach to network resilience that
encompasses the supply chain in the context of other social and physical
networks is needed in order to address the emerging challenges of a large-scale
COVID-19 vaccination program. We further find that the COVID-19 pandemic
underscores the necessity of positioning supply chain resilience within a
multi-network context and formally incorporating temporal dimensions into
analysis through the NAS definition of resilience, plan, absorb, recover,
adapt, to ensure essential needs are met across all dimensions of society.
